Dupuytren's contracture is a deforming condition of the hand in which one or more fingers contract toward the palm, often resulting in physical disability. The onset of Dupuytren's contracture is characterized by the formation of nodules in the palm that are composed primarily of collagen. As the disease progresses, the collagen nodules begin to form a cord causing the patient's finger(s) to contract, making it impossible to open the hand fully. This disease has a debilitating effect on quality of life, and patients often complain about their inability to perform necessary daily activities like washing their hands, wearing gloves or grasping objects. Dupuytren's contracture has a genetic basis and is most prevalent in individuals of northern European ancestry.

XIAFLEX® is the first and only FDA- and EMA-approved nonsurgical treatment for Dupuytren's contracture patients with a palpable cord.

Data from Year 3 of CORDLESS (Collagenase Optimal Reduction of Dupuytren's - Long-term Evaluation of Success Study) indicate that 87.2% of joints that achieved clinical success from XIAFLEX did not require further surgery or medical intervention. Additionally, a surveillance study based on three years of post-approval use of XIAFLEX indicates a safety profile with no clinically meaningful changes relative to the one year results. Adverse events were the most commonly localized, non-serious reactions to the injections.

For full prescribing information, please visit www.xiaflex.com.